

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR")

5 November 2025

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Letter of Intent signed with leading UK Clinical Diagnostic Group Providing Laboratory Services to the NHS

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to announce it has entered into a Letter of Intent ("LOI") with a leading medical diagnostic services provider (the "Provider") acting in partnership with the NHS. The LOI covers the verification and validation of the Company's CIZ1B biomarker test with a NHS Foundation Trust partner in state-of-the-art laboratories which may lead to the Provider being appointed as the Company's exclusive UK supplier of the CIZ1B test.

The discovery and development of the CIZ1B biomarker test is the result of many years of pioneering work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York. Initially supported by Yorkshire Cancer Research it has always been the ambition to ensure patients and healthcare professionals in the NHS and elsewhere should benefit from the Company's work in early cancer detection as part of its commercial roll out plans.

As part of the Company's commercial strategy to licence its proprietary test for the CIZ1B biomarker for use in the early detection of lung cancer globally, it has already secured a licence agreement in North America and the Caribbean, with guaranteed royalties and up-front fees of US 2.4 million, of which US 530,000 has already been received.

On 20 May 2025, the Company secured funding of £150,000 through the issue of convertible loan notes from the Company's existing shareholder, Frazer Lang to provide additional funding to support the Company's growth strategy, in particular to roll out its CIZ1B early cancer test in the UK and elsewhere in Europe. The intended partnership with the Provider, which for commercial reasons is confidential at this time, is a result of that programme.

Having established a route to market in North America and the Caribbean, the Company was keen to ensure that patients in the UK and then elsewhere in Europe, will also benefit from how the CIZ1B biomarker test can help in early lung cancer detection. This aligns with the current NHS cancer plan to improve cancer survival by increasing the proportion of cancers diagnosed at stages 1 and 2 with an aim to save 55,000 lives per year by 2028. A key element of this is improving access to early diagnosis, and increasing the number of cancers identified through screening.

Under the terms of the LOI, the Provider will immediately carry out a validation exercise with the Company and provide clinical input for the intended clinical indication of CIZ1B. Cizzle will provide on-site technical support under the guidance of Professor Coverley to confirm assay performance data. Following agreed success criteria, the parties will negotiate a Partnership Agreement for the commercialisation of the CIZ1B test. The Provider may then be appointed as the exclusive UK supplier of the CIZ1B test (subject to regulatory frameworks, including CE/UKCA/HIE requirements) and together, Cizzle and the Provider will jointly develop a go-to-market strategy, including co-branding and aligned communications. A commercial distribution model based on revenue share or a licensing structure, with a rollout strategy beyond the UK into Europe across private and NHS markets, will be negotiated.

The Company will also continue to focus on supporting its US partner Cizzle BIO Inc, to secure CLIA accreditation to take the test live in the near term, and on completing the ongoing Moffitt study to test patients with suspicious lung nodules in a clinical evaluation, as announced on 9 September 2024.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"We announced in May 2025 that while continuing to support the Company's licensing partner in North America, we would now be seeking an additional licensing partnership in the UK and rest of Europe. We are excited to report we have now entered a LOI with a leading UK provider with partnerships with NHS Foundation Trusts. Our goal is to provide a first-class service to help drive early cancer detection at scale globally. We are now pleased that the UK will be the next phase of our growth plans in making the test available to many patients as soon as possible.

Enquiries:

Cizzle Biotechnology Holdings plc

Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited

John Depasquale / Piers Shimwell (Corporate Finance)
Amrit Nahal (Sales and Corporate Broking)

+44(0) 20 3328 5656

IFC Advisory Limited

Tim Metcalfe
Florence Chandler

+44(0) 20 3934 6630

About Cizzle Biotechnology

The CIZ1B biomarker test for early-stage lung cancer is based on the pioneering work of Professor Coverley, the Founder and CSO of the Company, and her research team at the University of York. CIZ1 is a naturally occurring cell nuclear protein and the CIZ1B variant form is highly associated with the presence of early-stage lung cancer. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the diagnosis and detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to trading on the Main Market of the London Stock Exchange in May 2021.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seq.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

LOIBZLLBEFLLFBK